Open Access 01-03-2017 | Original Article
First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)
Published in: European Journal of Pediatrics | Issue 3/2017
Login to get accessAbstract
What is Known:
|
• Children with chronic lung disease have a 10-fold higher risk for RSV-positive hospitalization in comparison to healthy term infants and commonly receive palivizumab prophylaxis as a preventative measure against serious RSV-related lower respiratory tract infections.
|
• The American Academy of Pediatrics [
2
] and the Canadian Paediatric Society [
30
] have recently modified their recommendations for RSV prophylaxis in children with chronic lung disease, limiting palivizumab to either those <32 weeks gestation or those in the first year of life who are oxygen dependent or require medical therapy for the treatment of their condition.
|
What is New:
|
• Children with chronic lung disease receiving an additional course of palivizumab in their second year of life were determined to be at similar risk for both respiratory illness-related hospitalization and RSV-positive hospitalization as palivizumab-naïve children enrolled in the first year of life in the Canadian Registry for palivizumab (CARESS).
|
• CARESS physicians are correctly identifying high-risk children with chronic lung disease in their second year of life, whom they believe will benefit from an additional year of palivizumab prophylaxis, based on neonatal illness severity.
|